Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Payables (2016 - 2025)

CV Sciences (CVSI) has disclosed Payables for 14 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Payables fell 45.77% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 45.77% year-over-year, with the annual reading at $1.0 million for FY2025, 45.77% down from the prior year.
  • Payables hit $1.0 million in Q4 2025 for CV Sciences, down from $1.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.0 million in Q1 2021 to a low of $1.0 million in Q4 2025.
  • Historically, Payables has averaged $2.4 million across 5 years, with a median of $2.3 million in 2022.
  • Biggest five-year swings in Payables: surged 455.71% in 2021 and later crashed 45.77% in 2025.
  • Year by year, Payables stood at $3.2 million in 2021, then decreased by 29.42% to $2.3 million in 2022, then increased by 1.09% to $2.3 million in 2023, then fell by 16.63% to $1.9 million in 2024, then plummeted by 45.77% to $1.0 million in 2025.
  • Business Quant data shows Payables for CVSI at $1.0 million in Q4 2025, $1.2 million in Q3 2025, and $1.4 million in Q2 2025.